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Despite rising interest in the health problems ofthe elderly, information on senescence-related
alterations in essential metabolic pathways and their responses to various chemicals is scarce.
Although peroxisomal pathways are involved in a multitude ofcellular fnctions, little attention
has been given to the potential relationship between senescence ofthese organelles and the
process ofaging and disease.Although theprevailingexperimental evidence points to a decline in
liverperoxisomalenzyme activities andamutedresponse toperoxisome-proleratn chemicalsin
aged animals, it is also evident that aged animals are more susceptible, inl comparison to their
young counterparts, to the hepatocarcinogenic efecs of these chemicals. Furthermore, little is
known about extraperoxisomal effects ofperoxisome proliferators in aged animals. This review
evaluates published studies on the impat ofaging on basal hepatic:peroxisomal metabolism,
response to peroxisome proliferators, and changes in signal trauction pathways involved in
these processes, with the aim ofstimulating researchefforts in this important area. The potential
intricate relationship among senescent perosomes, aged hepatocytes, and health are also dis-
cussed. Keywordn. aging, peroxisomal disorders, peroxisome proliferator-activated receptors, per-
oxisomes. EnvironHealhPerspect107:791-797 (1999). [Online31August 1999]
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Aging has been defined as a progressive loss
of physiologic capacities that culminates in
death (1). Most physiologic functions decline
with age, although to different extents (1,2).
Evidence indicates that cells accumulate
damage over a lifetime (3). This slow incre-
mental damage results in the gradual loss of
differentiated functions and growth rate
accompanied by an increased probability for
the development ofcancer (3). Such changes
are normally held to a minimum by the orga-
nized state of the tissue and homeostatic
regulation ofthe organism (3).
Despite the myriad of peroxisomal
enzymes involved in essential cellular meta-
bolic pathways, little attention has focused
on the relationship among changes in the
basal activities of these enzymes, their
response to peroxisome-proliferating chemi-
cals, and the process of cellular aging. This
paucity of information is particularly alarm-
ing in light ofthe fact that the elderly popu-
lation, particularly in the industrialized
world, is exposed over its life span to an
ever-increasing number of peroxisome-pro-
liferating chemicals in the form oftherapeu-
tic agents and environmental pollutants.
Aging of the Liver
The liver, like most organs, is altered
morphologically and functionally in old
organisms; many age-related changes in
hepatocytes are similar to alterations
observed in other cell types [Table 1; (4,5)].
Therefore, common mechanisms of aging
may operate at the cellular level and cause
widespread decline in physiologic processes,
eventually culminating in death (5). The
aged liver has a reduced ability to regenerate
(6,7). Increases in mitosis in response to
hepatectomy or to chemicals are diminished
in old animals, as compared to their young
counterparts (6-9). Furthermore, the pool of
proliferating hepatocytes is smaller in old
animals, and is more sharply localized to
periportal hepatocytes (7). The importance
ofthese changes in aging is unclear.
Studies have produced conflicting data
on the effect of aging on the size of hepa-
tocytes. Although most studies described
conspicuous enlarged as well as small hepato-
cytes in old rats (7), others found far fewer
variations ofcell size, especially in female rats
(7). Interestingly, hepatocellular organelles
age faster than the cell (7). Mitochondria
appear to generally decrease in number and
size as a function of aging; the smallest
mitochondria with shortest cristae were
observed in the oldest rats (5,7). Similar
observations have been documented in both
mice and humans (7,10,11). Overall mito-
chondrial phosphorylation as well as turnover
ofmitochondrial proteins are reduced in the
aged liver (7,12). Similarly, the endoplasmic
reticulum seems diminished in aged animals
(7,13). In rats, studies have documented the
existence of an age-related decline in several
monooxygenase activities without any evi-
dence of significant changes in cytochrome
450 or reduced nicotinamide adenine
dinucleotide phosphate cytochrome reduc-
tase content (14). In contrast to the situation
in aging rats, mice demonstrate a decline in
several monooxygenase activities with age
(14). However, benzo[a]pyrene hydroxylase
and 7-ethoxycoumarin deethylase showed
significant increases in senescent mice (14).
Conversely, activity of liver cytosolic alcohol
dehydrogenase increased with age in male
Fischer 344 rats (15). However, activity of
this enzyme was not altered with age in
female rats, but was higher than in males in
both young and old rats (15). In contrast,
hepatic aldehyde dehydrogenase activity was
similar in both male and female rats and was
unchanged with age (15). Lysosomes are con-
spicuously increased in aged animals, with
their volume density reaching approximately
five times that at birth (7).
Peroxisomes: Function and
Proliferation
The peroxisome is a ubiquitous single
membrane-limited cytoplasmic organelle
present in animal, plant, and fungal cells
(16). Peroxisomes are most abundant in the
liver and kidney (17) and morphometric
studies show that there are between 370 and
620 peroxisomes per rat hepatocyte, occupy-
ing 1.5-2% of the cell volume (18). The
average peroxisome is approximately one-
fifth the volume of a mitochondrion (19).
Peroxisomal proteins are synthesized on free
polyribosomes, with most of them made at
their final size. These proteins are then post-
translationally imported from the cytosol
into peroxisomes, with half-lives ranging
from 1 to 15 min or longer (16).
Peroxisomefunction. Peroxisomes are res-
piratory organelles that play a role in cellular
oxygen consumption as well as in production
and removal of reactive oxygen species (20).
Peroxisomes are involved in a number of
essential cellular functions, including, but not
limited to, cellular respiration, gluconeogene-
sis, lipid metabolism, thermogenesis, and
synthesis of plasmologens (21). Among the
oxidases identified in peroxisomes are urate
oxidase, acyl-CoA oxidase, amino acid
oxidase, polyamine oxidase, trihydroxyc-
holestanoyl-CoA oxidase, and pristanoyl-
CoA oxidase (22). Peroxisomal 1-oxidation
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Table 1. Altered characteristics of senescent
hepatocytes.








Data derived from Makarides (4) and Dice (5).
offatty acids is among the best characterized
peroxisomal metabolicpathways. This system
is notafunctional duplicate ofthe mitochon-
drial system, as it is now clear that peroxi-
somes are involved in the degradation of a
distinct set ofcompounds such as the very
long-chain fatty acids and branched-chain
fatty acids (22). Oxidation of erucic acid,
arachidonic acid, and tetracosatetraenoic acid
is initiated in peroxisomes (22. Mammalian
peroxisomes are also a site for cholesterol and
etherlipid synthesis (22).
Peroxisomeprohferation. Various chemi-
cals, conditions, and factors cause peroxi-
some proliferation. This phenomenon was
first described in the 1960s. It was observed
that numerous electron dense single mem-
brane-limited structures appeared in rat liver
following clofibrate feeding (23). Since that
time, a myriad oftherapeutic agents, indus-
trial chemicals, and environmental pollu-
tants (Figure 1 and Table 2) of diverse
chemical structure have been shown to cause
peroxisome proliferation, particularly in
rodent livers (17,24). This group ofchemi-
cals has thus been referred to collectively as
peroxisome proliferators. In addition to
increasing the number ofperoxisomes, these
chemicals induce the activities of peroxiso-
mal enzymes and cause hepatomegaly (17).
These effects are not necessarily coupled,
although they are dose and time dependent
(17). Furthermore, these effects are tissue
and species specific (25-30), with the liver
being the most responsive tissue (17).
Although rats and mice are extremely
responsive to the effects of peroxisome
proliferators, guinea pigs are not and ham-
sters display an intermediate response
(17,26-28). Humans and other primates are
either insensitive or respond marginally to
peroxisome proliferators, both in vivoand in
vitro(17,26,28,29).
In addition to peroxisome-proliferating
chemicals, various other conditions and fac-
tors cause peroxisome proliferation, albeit
not to the same degree as with xenobiotics.
Among these conditions and factors are dia-
betes (31,32), changes in thyroid hormone
levels (33,34), cold adaptation (17), endo-
toxin exposure (35), high-fat diets (36), and
partial hepatectomy (37). These conditions
and factors are all believed to produce an
effect similar to that initiated by the peroxi-
some-proliferating xenobiotics.
Mechanisms involved in the response to
such a diverse group ofcompounds, factors,
and conditions are unclear. However, a
receptor-based mechanism for the pleiotrop-
ic response to peroxisome proliferators in
rodents has been suggested, where a nuclear
peroxisome proliferator receptor belonging
to the steroid hormone receptor superfamily
has been identified (38,3,9. This receptor is
activated by several peroxisome proliferators;
thus, it is termed the peroxisome prolifera-
tor-activated receptor (PPAR). Activation of
PPAR stimulates the expression of genes
encoding peroxisomal proteins (40).
Recently, three isoforms of the PPAR have
been found anddoned (41).
Prostaglandin 15-deoxy _AI2,14_ PGJ2
and the antidiabetic thiazolidinediones are
ligands for the PPARysubtype ofthis recep-
tor (Figure 1) (42). These chemicals pro-
mote differentiation ofpreadipocytes and act
as an insulin-sensitizing agent (43).
Activation ofPPAR6 subtype, however, was
not enough to potentiate preadipocyte dif-
ferentiation, nor did it result in modulation
ofglucose or triglyceride levels in vivo (43).
On the other hand, leukotriene B4 and sev-
eral known peroxisome-proliferating agents
including the hypolipidemic and hypocho-
lestermic WY-14,643 and fibrates, as well as
fatty acids and eicosanoids, bind specifically
to and activate PPARa (Figure 1) (44-47).
Activation of this receptor subtype signifi-
cantly reduces serum triglycerides, but with
minimal effects on hyperglycemia (43).
Studies have documented the existence
of a human form of PPARa (hPPARa)
(48,49) and PPARy (hPPARy) (50). The
tissue distribution pattern of hPPARa
mRNA is similar to that ofthe rat PPARa.
Both are highly expressed in the liver and
kidneys, whereas both are expressed at low
levels in the brain and lung, with lower lev-
els in most human tissues as compared to
rats (49,51). Interestingly, the relative
expression of PPARa mRNA in human
skeletal muscle is higher than in rodent
skeletal muscle (51). This finding may be
significant because studies focus almost
exclusively on the liver as a site to compare
the role ofPPARa in gene transcription in
humans and rodents.
Effect of Aging on
Peroxisomal Metabolism
Information on the relationship between
aging and peroxisomal metabolism is scarce.
Studies point to a general decrease in peroxi-
somal function with aging (52,53). However,
several studies failed to document measurable
differences in peroxisomal enzyme activities
Figure 1. Chemical structures of representative
peroxisome proliferator-activated receptor lig-
ands. (A) Physiologic ligands. (B) Xenobiotic
ligands.
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Table 2. Peroxisome proliferators in the environment."
Production in the Source and concentration
Chemical Major uses United States in the environment Human body burden Observed human toxicity
Diethylhexyl- Plasticizer 292,500,000 lb Drinking water(-30 ppb) 0.3-1.15 ppm in adipose Hepatic peroxisome proliferation in
phthalate Lubricating oils (1986) Groundwater(2.4 ppb) tissue dialysis patients
Insect repellant Surface water (1-80 ppb) Necrotizing enterocolitis in neonates
Cosmetic formulations Surface sediment(1-70 ppm) after insertion of umbilical catheters
Atmosphere (- 14ng/m3) CNS depression
Fish (0-16,000 pg/kg) Opacification ofthe lung
Milk(80 mg/L)
Dibutylphthalate Insect repellent 6,662,000 lb (1993) Drinking water(0.1-470 ppb) 0.1-0.8 ppm in adipose Severe keratitis
Plasticizer Groundwater (0.73-2.38 ppb) tissue Toxic nephritis
Solvent Surface water (0.1-0.6 ppb) Higher incidence of miscarriages
Solid rocket propellant Canned tuna (0-78 ppb) among exposed female workers
Fish (0.02-35 mg/kg)
Trichloroethylene Degreasing agent 320,000,000 lb Groundwater (30 ppb) 1-32 ppb in mother's Coma with eventual death from renal
Chemical and pharma- (1991) Surface water (1-24 ppb) milk, 0.1-9 mg% in or hepaticfailure
ceutical industry Atmosphere (15-16 ppt) blood Headache, dizziness, and sleepiness
Refrigerant Cheese (3 mg/kg) Skin irritation
Vegetable oil (7 mg/kg) CNS toxicities
Fruitjuices (5 mg/kg) Carcinogenicity
Fish(- 1 ppm)
Milk(0.3 mg/kg)
2,4-Dichlorophenoxy- Herbicide and other Over 5,000 lb (1991) Atmosphere and water near 0.4-6.3 mg/kg body Coma, myotonia, fever, pulmonary
acetic acid agriculture uses application or spill sites weight in urine of lawn emphysema, liver necrosis,
(concentration varies) care specialists using degeneration of kidneytubule,
Food (few mg/kg, except in the herbicide death
thevicinity ofspills)
Fish (0.1 mg/kg)
CNS, central nervous system.
Data extracted from a comprehensive search ofthe Hazardous Substances Data Bank(National Library of Medicine, Bethesda, MD).
between young and old animals (54,55).
Peroxisomes become smaller but more
numerous in older rats (7). In aged rats, per-
oxisomes show decreased catalase and acyl-
CoA oxidase content, but increased content
of thiolase and urate oxidase (56). The
decrease in catalase activity coupled with the
net increase in the activities ofoxidases are
thought to contribute to oxidative stress (57).
It has been shown that peroxisome prolifera-
tion was not accompanied byenhanced levels
ofoxidative damage in young mature animals
(24,58). However, whether aging lowers the
threshold for peroxisome proliferator-induced
oxidative stress is not known, but may be
implied from the enhanced susceptibility of
aged animals to thehepatocarcinogenic effects
ofperoxisome proliferators (55,59).
Basalperoxisomal enzyme activities in
aged animals. Apparent inconsistencies in
age-related effects on peroxisomal 5-oxida-
tion (Table 3) may have to do with species
differences and the age ofanimals at the time
of sacrifice, as opposed to their age at the
beginning ofthe experiment. Forexample, in
some studies animals were kept for extended
periods, which resulted in younger and older
animals being senescent at the time ofsacri-
fice (Table 3). Another potential reason for
these apparent disparate results may reside in
the ages ofanimal groups used, as peroxiso-
mal enzyme activities appear to change dra-
matically and abruptly at certain age points
during development and aging (52). The
Table 3. Effect of age on hepatic peroxisomal
P-oxidation.
Species Younga,b Olda,b Reference
Male Fischer 100(17) 117 (28) (55)
344rats 100(8) 115(20) (54)
100(2) 92(13) (60
Female CSWV mice 100(11) 28(20) (52)
Female OFi mice 100(11) 61(24) (53)
'Results are expressed as percent of specific activity in
young animals within the same study. bNumbers in
parentheses indicate age of animals, in months, at time
ofsacrifice.
dedine ofcatalase activity with aging in male
Fischer 344 rats has been observed in various
studies (Table 4). In our laboratories, hepatic
catalase activitydeclined by40% between the
ages of 4 and 100 weeks, with most of the
decline (30%) observed between the ages of
50 and 100 weeks (Table 4). Similarfindings
were also observed by others (52) for both
peroxisomal P-oxidation and catalase in both
CSWV and OFi mice strains (Tables 3 and
4), and similar findings were reported for the
enzymatic activity and mRNA coding for
catalase in rat liver (63,64). Transcription of
the catalase gene decreased by approximately
60% between 6 and 29 months ofage (64).
Thus, the age-related decline in catalase
mRNA levels appears to arise primarily from
a decrease in the transcription of the gene
(64). Quantitative analysis ofkinetic parame-
ters (rates of protein synthesis and degrada-
tion) revealed that theaged rat liver exhibited
Table 4. Liver catalase in animals ofvarious ages.
Species Youngasb Oldasb Reference
Male Fischer 100(3) 63(24) (61)
344 rats 100(5) 48(26) (62)
100(6) 60(26) (63)
100(6) 61 (24) (64)
100(6) 48(29) (64)
Female CSWV mice 100(11) 71(18) (52)
Female OFi mice 100(11) 66(24) (53)
'Results are expressed as percent of specific activity in
young animals within the same study. bNumbers in
parentheses are age of animals in months.
a decrease in rates of catalase synthesis
without significant changes in degradation
rates (65).
Peroxisomeproliferation inagedanimals.
Aging also interferes with the ability of the
liver to respond to peroxisome-proliferating
chemicals (60). Peroxisomal area relative to
hepatocellular cytoplasmic area increased by
approximately 7-fold in both 8- and 52-
week-old rats following 14 days ofdaily 200-
mg/kg clofibrate doses in diet; it increased
only by 4-fold in 117-week-old rats (60). In
the same rats, increases in hepatic peroxiso-
mal f-oxidation showed a similar pattern,
with increases approaching 15- and 11-fold
in 8- and 52-week-old rats, but only3-fold in
the 117-week-old rats (60). In our laborato-
ry, perfluorooctanoic acid (PFOA) induced
peroxisomalP-oxidation significantly in male
Fischer 344 rats ofvarying age groups to dif-
ferent levels. Forty-eight hours after 150
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mg/kg PFOA administration, hepatic peroxi-
somal P-oxidation increased in 100-week-old
rats to levels equaling approximately 60% of
those achieved in 10-week-old rats (Table 5).
In contrast to the PFOA findings, and in
agreement with results reported in the lite-
rature (54), young and old male Fischer 344
rats given various concentrations of the per-
oxisome proliferator WY-14,643 in the diet
exhibited comparable hepatic peroxisomal I-
oxidation activity (Table 5). Similarly, a
study in male Wistar rats showed thatage did
not seem to influence either basal or
nafenopin-induced induction ofperoxisomal
P-oxidation (55). In these long-term feeding
studies (54,55), animals were given diets
containing peroxisome proliferators for
22-59 weeks, which placed the age of
young and old rats between 68 and 116
weeks at the conclusion of the experiment.
Potentially, these are ages where responses
to peroxisome proliferators are similar. In a
more detailed study in our laboratories (66),
striking results showing compound-specific
effects were observed (Table 6). Although
aging-related differences appeared to exist in
the response of the liver to certain peroxi-
some proliferators, aging did not seem to
influence the response to other peroxisome
proliferators studied (Table 6). The lack of
uniformity in the response to various perox-
isome proliferators may be due to potential
aging-related alterations in specific pathways
Table 5. Induction of liver peroxisomal P-oxidation
byvarious peroxisome proliferators in aged animals.
Species Youngab Olda,b Reference
Male Fischer 100(3)C 44(25)c (61)
344 rats 100 (2)d 68(13)d (60L
100 (8)e 85(20)e (54)
Female OFi mice 100(11)f 70(24)f (53)
&Results are expressed as percent of peroxisome prolif-
erator-induced specific activity in young animals within
the same study. bNumbers in parentheses are age of ani-
mals in months. cAnimals were given perfluorooctanoic
acid (150 mg/kg, orally in corn oil 48 hr priorto sacrifice).
dAnimals were given clofibric acid in the diet (various
concentrations to correspond to 200 mg/kg/day for 14
days). "Animals received WY-14,643 in the diet (0.1% for
22 weeks). fAnimals received clofibrate-supplemented
diet(0.5% for 5 days).
Table 6. Age-related responses of hepatic peroxi-
somal ,-oxidation to various peroxisome prolifer-
ators.
Young Old
Compound (10weeks old)a (100weeks old)
PFOA 1oob 62b *
WY-14,643 1OOC 93c
DEHP 137d*
Abbreviations: DEHP, diethylhexylphthalate; PFOA, per-
fluorooctanoic acid.
aResults are expressed as percent of hepatic enzyme
specific activity in young rats. h150 mg/kg. C250 mg/kg.
dl.2 g/kg. Drugs in corn oil were given orally 48 hr priorto
sacrifice. *Significantly different from corresponding
young animal group.
involved in the metabolism ofspecific pro-
liferators. In other words, peroxisomal
signal transduction pathways are most likely
altered in old animals, as evidenced by the
significant differences observed between
young and old animals in response to the
nonmetabolizable PFOA.




Factors responsible for the reported decline
in peroxisomal enzyme activities and the
diminution oftheir response to peroxisome-
proliferating chemicals in aged animals are
unclear. Aschematic depiction ofaproposed
mechanism involved in this effect is present-
ed in Figure 2. The aged liver suffers from a
defect in gene transcription and translation
of certain messengers (67). This defect may
be the result of deficiency in important
receptors and/or impaired signal transduc-
tion pathways. Recent findings show that
expression of nuclear thyroid hormone
receptor mRNA is reduced by 50% in the
livers of male Wistar rats 24 months old as
compared to their 6-month-old counterparts
(68). This decrease was not accompanied by
changes in the binding characteristics ofthe
receptors, although Bma and Kd decreased
by approximately 2-fold in the older rats.
Similar changes were also observed for the
mRNA of retinoic acid receptors (68). An
overlap between the gene networks regulated
by peroxisome proliferators and those for
retinoids and thyroid hormones has been
documented (57). PPARs, thyroid receptors,
and retinoid receptors (RXR) recognize the
same DNA response sequence and there is
cross-talk among these receptors (57,69).
PPAR binds to peroxisome proliferator-
response elements as heterodimers with RXR
and activate gene transcription in response
to activators (70). Furthermore, RXR lig-
ands produce effects similar to those pro-
duced by PPARligands (70).
Peroxisome proliferators induce malic
enzyme gene transcription, which is a
known response to treatment with thyroid
hormones (68), through the action of
heterodimers of PPARot and RXR (71). In
addition to changes in receptor abundance
and affinity, aging also causes modifications
in cellular transduction pathways, leading to
altered gene expression, which may be
responsible for some important impairment
in physiologic functions (67). The decrease
in receptor affinity in aged animals is
hypothesized to be due to changes in the
phosphorylation-dephosphorylation cycle in
these animals (68). The potential impact of
aging on the expression ofthe various peroxi-
some proliferator-activated receptor isoforms
and/or binding ofperoxisome-proliferating
chemicals to these receptors is shown by a
decline in the abundance ofPPARa mRNA
expression in the liverofaged rats (72.
Aging, Peroxisomes, and
Health
The importance ofthe peroxisome to animal
as well as to human life is evidenced by the
fact that their absence, or thedysfunctionali-
ty of one or more peroxisomal enzymes, is
invariably fatal (73,74). In addition, inhibit-
ingperoxisomal enzyme activities resulted in
the accelerated death ofanimals (75), which
suggests the existence of a linkage between
peroxisomal metabolism, aging, and death.
However, the exact nature of a potential
relationship is notknown.
Inherited peroxisomal disorders.
Peroxisomal disorders are a group ofinherit-
ed metabolic diseases that are classified into
10 complementation groups (76). These dis-
eases involve multiple genes (76) and are
characterized by impairment ofone or more
functions ofperoxisomes (73,74,76). Recent
studies have suggested that at least 16 genes
may be involved in the observed abnormali-
ties in the assembly ofperoxisomes (74,77),
and the list ofperoxisomal disorders contin-
ues to grow (76). The combined incidence
for the occurrence of these diseases is esti-
mated as 1 in 20,000 or greater (74). The
cerebrohepatorenal syndrome known as
Zellweger syndrome was the first peroxiso-
mal disorder identified (74,78). This syn-
drome is characterized by the absence of
morphologically distinguishable peroxisomes
(74). In contrast to Zellweger syndrome,
patients suffering from X-adrenoleukodys-
trophy have peroxisomes ofnormal number
and morphology, and the disease is caused
by a single enzymatic abnormality; ligno-
ceroyl-CoA ligase is suggested as the missing
enzyme (74,79). Other diseases such as rhi-
zomelic chondrodysplasia are recognized as
multiple peroxisomal enzymatic deficiencies,
although they have intact peroxisome mor-
phology, normal size, and number (74,80).
Aging, apoptosis, andresponse toperoxi-
someproliferators. Aged animals are more
susceptible to the hepatocarcinogenic effect
of peroxisome proliferators (55,59). Long-
term treatment with either of the peroxi-
some-proliferating chemicals nafenopin or
WY-14,643 produced numerous hepatocel-
lular adenomas and carcinomas in old male
Wistar and Fischer 344 rats while producing
only a few changes in young animals
(55,59). Because the enhanced susceptibility
of old rats did not appear to result from
enhanced hepatic oxidative damage, it was
hypothesized that peroxisome proliferators
may promote spontaneously occurring pre-
neoplasticfoci. These foci are moreabundant
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in the livers ofaged animals as a natural con-
sequence ofaging (59). Hypolipidemic drugs
are preferentially prescribed to older individ-
uals who may have high levels ofpreneoplas-
tic hepatocytes. Promotion of these cells by
peroxisome proliferators has the potential to
result in liver cancer.
As an alternative mechanism responsible
for the hepatocarcinogenic effect of peroxi-
some proliferators, several studies have
shown that peroxisome proliferators suppress
apoptosis in the liver in a process mediated
by PPARa (81,8.). Apoptosis appears to be
a safeguard to prevent cells with DNA dam-
age from progressing to a tumor (83). In pri-
mary cultures of rat hepatocytes and in an
FaO rat hepatoma cell line, apoptosis was
induced by transforming growth factor P,
an effect thatwas significantly reduced by the
coadministration ofthe peroxisome prolifera-
tor nafenopin (84). Furthermore, nafenopin
suppressed hepatic apoptosis in vivo and its
Figure 2. Schematic depiction ofthe effect ofaging on proposed signaling pathways involved in maintain-
ing and proliferating hepatic peroxisomes. Abbreviations: GR, glucocorticoid receptor; PPAR, peroxisome
proliferator-activated receptor; RXR, retinoic acid receptor; TR,thyroid hormone receptor. Aging is asso-
ciated with a decline in GR,TR, and RXR. The compromised integrity ofthese systems, along with a poten-
tial decline in PPAR expression and/or activation with aging may be responsible forthe diminished basal
levels of peroxisomal enzyme activities and their response to peroxisome proliferators in aged animals.
withdrawal resulted in a 100- to 200-fold ele-
vation in apoptosis (84). Hepatocytes gener-
ated during nafenopin-induced hyperplasia
were not the same as those that underwent
apoptosis upon nafenopin withdrawal (84).
Hepatocytes resistant to apoptotic death
may represent preferential targets for promo-
tion by peroxisome proliferators; thus, sup-
pression of apoptosis may play a role in the
hepatocarcinogenicity of this class of
nongenotoxic compounds. Current evidence
indicates that the signal transduction path-
ways for apoptosis and the cell cycle overlap
(85). Senescent cells are resistant to both pro-
liferation and apoptotic stimuli, possibly
because oftheir failure to induce the expres-
sion of G] genes, which are required for both
outcomes, when subjected to stimulation
(85). An alternative hypothesis to explain the
resistance ofsenescent cells to apoptosis stip-
ulates that these cells have the protein ter-
minin predominantly in its 60-Kda form, in
contrast to the 90 Kda in apoptotic-prone
cells (85). Resistance to apoptosis may con-
tribute to the enhanced vulnerability of the
aged liver to the hepatocarcinogenic effect of
peroxisome proliferators.
Conclusion
The importance of peroxisomes to normal
cell functions and cellular survival makes the
investigation ofwhether these organelles play
a role in aging and aging-related diseases an
urgent task. Research in the field of peroxi-
somes has until recently focused on these
organelles and their proliferation, particularly
in the rodent liver. Because peroxisomes do
not seem to proliferate to significant levels in
the livers ofhumans exposed to peroxisome-
proliferating chemicals, pre-mature conclu-
sions were drawn that dismissed the potential
risk these chemicals pose to humans.
However, recent advances show that signal
transduction pathways linked to peroxisomes
are involved in a myriad ofextraperoxisomal
effects. Examples of these effects include
adipocyte differentiation, regulation ofglu-
cose homeostasis, inhibition of macrophage
and monocyte activation, and inhibition of
angiogenesis (42,43,86,87). Although several
ofthese effects appear beneficial, others may
potentially be harmful. Therefore, it is
imperative that a concerted and comprehen-
sive effort is channeled toward investigating
a wide array of potential effects due to per-
oxisome-proliferating chemicals. A signifi-
cant portion ofthis effort should be directed
toward the elderly population, which might
be more vulnerable to these effects.
Membrane structure, fluidity, and per-
meability to ions undergo some age-depen-
dent alterations (53,88,89). These alterations
have serious inhibitory effects on the enzy-
matic catalysis rates involved in protein
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synthesis that may be responsible for the
decline in protein synthetic capacity in aged
cells and may also contribute to the onset of
age-related diseases (53,88,89). For exam-
ple, membrane fatty acid composition
affects membrane structure and function
(90). Membrane fatty acid composition is
maintained through a balanced process of
synthesis and degradation. Although degra-
dation of long-chain fatty acids occurs in
both mitochondria and peroxisomes, very
long-chain fatty acids are metabolized exclu-
sively in peroxisomes (91). Thus, peroxi-
somes appear to play an important role in
the maintenance of membranes and mem-
brane function by maintaining fatty acid
balance. Consequently, the decline in perox-
isomal catabolism of fatty acids with aging
may represent a potential mechanism by
which these organelles are involved in the
process ofaging.
An aging-related decline in peroxisomal
protein synthesis, among other proteins, is
expected to diminish peroxisomal capacity to
metabolize very long-chain fatty acids. This
effect may be manifested in an altered com-
position of the structure of cellular and
organellar membranes. For example, it has
been reported that aging causes an increase
in the cholesterol:phospholipid ratio in rat
liver microsomal, mitochondrial, and cellular
membranes (88,90). Phospholipids are
essential for the activation ofvarious signal
transduction pathways. This includes the
modulation of protein kinase C activity by
phosphatidylserine and various other mem-
brane phospholipids (92). Accordingly,
changes in membrane phospholipids as a
result ofage-related diminished peroxisomal
metabolism may trigger a cascade ofharmful
events and/or interrupt normal important
cellular functions.
Aging-associated changes in membrane
phospholipid composition are also reflected
by an increase in Na, K-ATPase activity,
and intracellular potassium content (88).
Increased intracellular ion concentrations
are postulated to reduce the activity of the
whole translational machinery and increase
aggregation of macromolecules, which
retard all enzymatic catalysis (88,93) and
interfere with mitotic activity (94).
The impact of aging on extracellular
matrix, growth factors, cytokines, and non-
parenchymal cells, among other factors, will
be ofutmost importance to our understand-
ing of the relationship between aging and
peroxisomal metabolism. Because these fac-
tors play important roles in liver cell division
(95,96), their alterations with aging may
explain the potential interrelationship
between peroxisomal metabolism and aging-
related disease and death. Peroxisomes grow
by the posttranslational incorporation of
new content and membrane proteins into
preexisting peroxisomes, which then divide
to form daughter peroxisomes in a dynamic
fission process (16). Consequently, a vicious
cycle involving hepatocellular senescence and
a decline in peroxisomal metabolism may
ensue, leading to the demise ofthe liver and
ultimately to death.
Peroxisome-proliferating chemicals pro-
duce a myriad ofextraperoxisomal effects in
the liver and other tissues of experimental
animals (24). Such effects include metabolic
as well as hormonal alterations, in addition
to effects on ion homeostasis and interfer-
ence with metabolism and effects of other
chemicals (24). These extraperoxisomal
effects may be directly or indirectly related
to the effects on peroxisomes or may be
totally independent ofthese events. Whether
any or all of these effects occur in humans
exposed to peroxisome proliferators is not
known. Focusing only on the peroxisomal
effects ofthese chemicals may grossly under-
estimate the harmful potential ofperoxisome
proliferators to humans, especially the elder-
ly, who are more susceptible to toxic insults.
Furthermore, because of the essential roles
played by peroxisomal metabolism, the pos-
sibility that modulation ofperoxisomal func-
tions may be a contributing factor to the
process ofaging should not be ignored.
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